Indivior PLC (LON:INDV - Get Free Report) was up 11.9% during trading on Thursday . The stock traded as high as GBX 738 ($9.58) and last traded at GBX 731 ($9.49). Approximately 231,070 shares changed hands during trading, a decline of 82% from the average daily volume of 1,264,178 shares. The stock had previously closed at GBX 653.50 ($8.48).
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a GBX 1,500 ($19.48) price target on shares of Indivior in a research note on Thursday, September 5th.
Read Our Latest Report on Indivior
Indivior Price Performance
The stock has a market capitalization of £888.56 million, a P/E ratio of -863.75, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The company has a debt-to-equity ratio of 2,790.00, a current ratio of 0.85 and a quick ratio of 1.52. The company's 50-day simple moving average is GBX 774.08 and its 200-day simple moving average is GBX 1,087.15.
Insider Activity
In other Indivior news, insider Jo Le Couilliard acquired 1,490 shares of the business's stock in a transaction dated Friday, July 26th. The stock was bought at an average cost of GBX 1,006 ($13.06) per share, with a total value of £14,989.40 ($19,461.70). 3.44% of the stock is owned by insiders.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
